1. In Vivo
  2. >>Business Strategy

With Genoptix, Novartis Continues Its Diagnostics Build-up

Novartis' $440 million offer for cancer testing services lab Genoptix is another sign of the pharma giant's intent to build a full-blown molecular diagnostics business. The acquisition adds muscle to its existing Molecular Diagnostics unit. Coming just months after GE grabbed up Clarient, it is another example of the value of a specialty cancer services testing operation to an organization looking to bolster channel access to oncologists and pathologists.

Novartis AG's $440 million cash tender offer for cancer testing lab Genoptix Inc. is another sign of the pharma giant's intent to build a full-blown molecular diagnostics business. [See Deal] The acquisition adds more muscle to its two-and-a-half-year-old Novartis Molecular Diagnostics unit. Just months after GE Healthcare, a division of General Electric Co., grabbed up Clarient Inc. for $570 million, the deal is also another example of the perceived value of a specialty cancer services testing capability for an organization looking to bolster its channel access to oncologists and pathologists. [See Deal]

Genoptix offers personalized diagnostics services to community-based oncologists, focusing on hematological malignancies and, more recently and to a lesser extent,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.